Skeletal Muscle Magnetic Resonance Imaging of the Lower Limbs in Late-onset Lipid Storage Myopathy with Electron Transfer Flavoprotein Dehydrogenase Gene Mutations

Xin-Yi Liu¹, Ming Jin¹, Zhi-Giang Wang¹,², Dan-Ni Wang¹, Jun-Jie He¹, Min-Ting Lin¹, Hong-Xia Fu¹, Ning Wang¹,²
¹Department of Neurology and Institute of Neurology, First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian 350005, China
²Fujian Key Laboratory of Molecular Neurology, Fuzhou, Fujian 350005, China

Abstract

Background: Lipid storage myopathy (LSM) is a genetically heterogeneous group with variable clinical phenotypes. Late-onset multiple acyl-coenzyme A dehydrogenation deficiency (MADD) is a rather common form of LSM in China. Diagnosis and clinical management of it remain challenging, especially without robust muscle biopsy result and genetic detection. As the noninvasion and convenience, muscle magnetic resonance imaging (MRI) is a helpful assistant, diagnostic tool for neuromuscular disorders. However, the disease-specific MRI patterns of muscle involved and its diagnostic value in late-onset MADD have not been systematic analyzed.

Methods: We assessed the MRI pattern and fat infiltration degree of the lower limb muscles in 28 late-onset MADD patients, combined with detailed clinical features and gene spectrum. Fat infiltration degree of the thigh muscle was scored while that of gluteus was described as obvious or not. Associated muscular atrophy was defined as obvious muscle bulk reduction.

Results: The mean scores were significantly different among the anterior, medial, and posterior thigh muscle groups. The mean of fat infiltration scores on posterior thigh muscle group was significantly higher than either anterior or medial thigh muscle group (P < 0.001). Moreover, the mean score on medial thigh muscle group was significantly higher than that of anterior thigh muscle group (P < 0.01).

Conclusions: Late-onset MADD patients show a typical muscular imaging pattern of fat infiltration and atrophy on anterior, posterior, and medial thigh muscle groups, with major involvement of posterior thigh muscle group and gluteus muscles and a sparing involvement of anterior thigh compartment. Our findings also suggest that muscle MRI of lower limbs is a helpful tool in guiding clinical evaluation on late-onset MADD.

Key words: Electron Transfer Flavoprotein Dehydrogenase; Fat Infiltration Atrophy; Late-onset Lipid Storage Myopathy; Magnetic Resonance Imaging; Multiple Acyl-coenzyme A Dehydrogenation Deficiency

Introduction

Late-onset lipid storage myopathy (LSM) is an autosomal recessive muscular disorder associated with errors of fatty acid, amino acid, and choline metabolism. The four main genetic causes of LSM are multiple acyl-coenzyme A dehydrogenation deficiency (MADD, OMIM 231680), primary carnitine deficiency (OMIM 212140), neutral lipid storage disease with myopathy (OMIM 610717), and neutral lipid storage disease with ichthyosis (OMIM 25630).¹ The mutations of electron transfer flavoprotein dehydrogenase (ETF DH) gene have been described in a considerable number of patients²⁻³ and MADD appears to be a rather main form of LSM in Chinese population.⁴ Previous data indicated that the ETFDH-c.250G>A had a high mutation frequency in Southern China whereas c.770A>G and c.1227A>C were more widespread hot spot mutations in both Southern and...
The clinical symptoms of late-onset MADD are heterogeneous, varying from pure muscle weakness to serious metabolism crisis. Patients predominantly present in adolescence or adulthood with episodes of proximal myopathy, exercise intolerance, vomiting, hypoglycemia, and encephalopathy usually triggered by metabolic stress.\[17\]

Since the clinical manifestations of late-onset MADD are highly heterogeneous and relatively unspecific, the ultimate diagnosis is based on a standard muscle biopsy and genetic analysis, none of which is widely available on different levels of hospitals. Moreover, patients refuse the invasive muscle biopsy occasionally. In such situation, we need a helpful and practical tool to formulate a reasonable diagnosis or limit the differential diagnosis. In the last decade, as a noninvasive tool in the diagnosis, various muscle magnetic resonance imaging (MRI) patterns of neuromuscular diseases have been found. MRI allows detection and characterization of much muscular pathology, such as inflammation, atrophy, edema, and fat infiltration. For diagnostic purposes, T1- and T2-weighted axial images of lower limbs may be sufficient for muscular dystrophy.\[10\] Hence, muscle MRI has been widely used in accessory diagnosis of spinal muscular atrophy,\[9\] limb girdle muscular dystrophy (LGMD),\[10\] Duchenne muscular dystrophy/Becker muscular dystrophy (DMD/BMD),\[11\] and congenital muscular dystrophy (CMD),\[12\] especially in the absence of robust muscle biopsy results. Recently, a case report highlighted the diagnostic clues and body fat MRI in metabolic disorders.\[13\] Indeed, muscle MRI pattern in late-onset MADD due to ETFDH gene mutations has not been systematic analyzed and concluded. Based on our initial clinical, genetic, and treatment studies in a large cohort of Chinese patients with late-onset MADD,\[5,14\] we were interested to characterize the disease-specific patterns of involved muscle by the pelvic girdle and thigh muscles MRI to help in diagnostic work-up, exploring the diagnostic value of muscle MRI on late-onset MADD.

Methods

Patients

In total, 28 patients (18 males and 10 females) visited the First Affiliated Hospital of Fujian Medical University from January 2012 to December 2015, and these patients were pathologically and genetically diagnosed as late-onset MADD and recruited to perform the muscle MRI scan of pelvis and thigh muscles. In addition, cases involving lipid storage abnormalities secondary to steroids and mitochondrial diseases were excluded. This study was approved by the Ethical Committees of the First Affiliated Hospital of Fujian Medical University.

Data collection

Basic information, including gender, age, onset age, and family history, was first collected. Before riboflavin treatment, manual muscle testing (MMT), blood biochemistry, muscle biopsy, abdominal ultrasonography, electromyography (EMG), and acylcarnitine and urine organic acids profile were performed. Muscle strength grade in MMT scoring was counted and referenced to Kendall 0–10 point scale as previously described.\[15,16\] The strength of 14 muscles distributed in neck, proximal limb, and distal limb was examined. The neck muscles were neck flexion and neck extensor. The proximal limb muscles contained deltoid, biceps, triceps, iliopsoas, gluteus medius, gluteus maximus, posterior group, and quadriceps femoris. The muscles in distal limb were wrist flexion, wrist extension, ankle dorsiflexion, and ankle plantar flexion.

Blood biochemistry test items were creatinine kinase (CK), MB isoenzyme of CK, aspartate amino transferase (AST), lactate dehydrogenase (LDH), and blood lactic acid deficiency (LAC). Blood acylcarnitine and urine organic acid profiles were analyzed by tandem mass spectrometry (MS/MS) and gas chromatography-mass spectrometry, respectively. Hematoxylin-eosin (HE) and oil red O (ORO) staining were carried out.

Mutation detection

After informed consent, peripheral blood samples were collected from these patients and their available immediate relatives. DNA was abstracted using DNA extraction kit (Qiagen, Hilden, Germany). Polymerase chain reaction (PCR) was performed to amplify the exons of ETF4A, ETFB, and ETFDH genes. The PCR products were purified for Sanger sequencing. The primers and reaction condition referred to the published literature.\[5\]

Muscle magnetic resonance imaging

MRI scans of the lower limbs were performed on a 3.0-T whole-body scanner (Magnetom Verio; Siemens AG, Erlangen, Germany) before riboflavin treatment. Coronal, horizontal, and anteroposterior axial planes of the pelvis and bilateral thighs were obtained by the conventional T1- and T2-weighted spin-echo sequences. Short tau inversion recovery (STIR) sequences for fat suppression were also available for all the individuals. Sections were generally analyzed with pelvis and mid-upper thighs, for the reason that muscle bulk is greatest at this level and that muscle abnormality could be more clearly visualized.\[17\] The combination of T1-/T2-weighted imaging with STIR sequences was used to assess the degree of muscle fat infiltration and atrophy. Individual thigh muscles were scored for fat infiltration, including anterior (sartorius, rectus femoris, vastus lateralis, vastus intermedius, and vastus medialis), medial (gracilis, adductor longus, adductor brevis, and adductor magnus), and posterior thigh muscle groups (biceps femoris, semitendinosus, and semimembranosus). The degree of fat infiltration in single muscle is described as follows: Grade 0, normal; Grade 1, punctate hyperintense; Grade 2, mildly abnormal (fatty streaks detected below 30% muscle volume); Grade 3, moderately abnormal (hyperintense detected among 30–60% muscle volume); Grade 4, severely abnormal (hyperintense detected above 60% muscle volume); and Grade 5, terminal stage (hyperintense in the whole muscle).\[18-20\] As glucose with rich fascia and connective tissue, the accurate score was unavailable. The frequent of...
Gluteus involvement was calculated to represent the degree of fat infiltration in gluteus. Muscular atrophy was defined as obvious muscle bulk reduction.

**Statistical analysis**
The scores were averaged to produce mean fat infiltration scores for each muscle group. The mean scores were compared among muscle groups using one-way analysis of variance. The comparison between two muscle groups was conducted by Dunnett’s T3 test due to the heterogeneity of variance. \( P < 0.01 \) indicated statistical significance. Analysis was performed using SPSS 19.0 software (SPSS Inc., Chicago, IL, USA).

**Results**

**Clinical manifestations**
Among the 28 patients, the mean onset age was 21.0 ± 11.1 years, ranged from 3 to 55 years. The age of initial clinical assessment ranged from 10 to 58 years. Proximal muscle weakness was found as the most frequent initial symptom in 24 patients (85.7%). All patients exhibited exercise intolerance and weakness of proximal limbs as well as neck muscle. Sixteen (57.1%) patients displayed gastrointestinal symptoms, such as nausea, vomiting, or diarrhea. Dysmasesis and dysphagia were observed in 17 and six patients, respectively. Two patients had myalgia. In physical examination, two patients were found to have muscle atrophy in bilateral thighs. When analyzed the muscle strength, the most severely involved muscles were neck muscle, deltoid, iliopsoas, gluteus maximus, and gluteus medius. The means of lower limbs muscle strength are summarized in Figure 1. All the distal limbs and quadriceps femoris were not clinically affected. Clinical manifestations of the patients are summarized in Table 1.

**Mutation**
Among the 28 patients, five missense mutations in *ETFDH* were detected, including c.250G>A, c.380T>A, c.770A>G, c.1601C>T, and c.524G>A. Twenty-one patients (75.0%) were c.250G>A homozygote, as well as five heterozygous patients also carried c.250G>A. The remaining two patients showed compound heterozygous mutations without hot spot. Three patients complained a suspect family history of this disease and six patients had heterozygous parents. Neither *ETF4* nor *ETFB* mutation was discovered.

**Blood biochemistry**
The median and range of CK, AST, LDH, and LAC are summarized in Table 1. For most patients, the muscle enzyme values ranged from normal to 29 times of normal upper limits [Table 1]. Twenty-two patients (78.6%) showed a high LAC level. In the blood acylcarnitine profile test, 21 patients (21/28, 75.0%) represented increased multiple acylcarnitines while three patients showed decreased multiple acylcarnitines and free carnitine. The remaining patients were normal. In urine organic acids test of 26 patients, nine patients (34.6%) showed ketonuria and the remaining 17 patients were normal.

**Electromyography, abdominal ultrasonography, and muscle pathology**
For the EMG examination, 25 patients (89.3%) were found myopathic changes and the remaining were neurogenic or no obvious myopathic changes. For twenty patients carried abdominal ultrasonography examination, six patients (30.0%) showed fatty liver in varying degrees.
All the patients showed vacuolus on HE staining and lipid droplets deposition on ORO staining of the muscle fibers.

**Muscle magnetic resonance imaging**

There was obvious variability in the severity degree of muscle MRI results among the patients included. Two patients were sparing of muscle involvement whereas the other 26 patients symmetrically developed mild to severe muscle involvement, including fat infiltration and atrophy [Figures 2–4]. Muscle involvement could be identified in patients with either homozygous mutation or compound heterozygous mutation [Figures 3 and 4]. The detailed muscle fat infiltration scores of each patient are listed in Supplement Table 1. At thigh level, a major involvement of the posterior thigh muscle group was noticeable. The mean scores for fat infiltration of anterior, medial, and posterior thigh muscle groups were 0.13 ± 0.22, 0.47 ± 0.40, and 1.35 ± 0.75, respectively. The mean scores were significantly different among the three groups of thigh muscles ($P < 0.001$). In the comparison of each two muscle groups, the mean of fat infiltration scores on posterior was significantly higher than either anterior or medial thigh muscle group ($P < 0.001$) [Figure 5]. Moreover, the mean on medial thigh muscle group was significantly higher than that of anterior thigh muscle group ($P < 0.01$) [Figure 5]. Twelve patients (42.9%) exhibited thigh muscle atrophy, especially in medial and posterior thigh muscle groups. Of 24 patients, 15 (62.5%) who conducted gluteus muscle MRI displayed fat infiltration and atrophy in gluteus muscles. Twelve patients showed atrophy especially in medial and/or posterior thigh muscle groups, which had the similar distribution with fat infiltrated muscles, especially in posterior group. It was worth noting that increased STIR signal, suggestive of edema and inflammation, was found in none of pelvic and thigh muscles in our patients [Table 2].

**Discussion**

In this study, we have identified and evaluated the muscle MRI finding in a cohort of late-onset LSM patients carried pathological ETFDH gene mutations. Our results indicated that lower limbs MRI is an additional and helpful tool in guiding the clinical diagnosis of late‑onset MADD.

A previous MRI findings about MADD have described those T2 hyperintense lesions in the bilateral globus pallidus in a young child with neonatal-onset form. While a recent report using whole-body MRI revealed an increase subcutaneous fat but normal visceral fat, despite fatty liver...
and lipid storage in muscle, in a young patient with a novel homozygous missense mutation in \textit{ETFDH} gene.\cite{13} These studies only paid attention on the brain lesion or body fat distribution. Herein, we focused on the lower limbs muscle

MRI findings, including fat infiltration and atrophy, in a group of patients with clinical, pathological, and genetic diagnosed as late-onset MADD. The complete clinical information allowed us to provide a systematic analysis of the muscle MRI pattern and correlate the severity of the MRI finding with the severity of clinical impairments.

MRI plays an important role in detecting alterations in muscle morphology and signal intensity characteristics associated with many neuromuscular disorders although a limited number of nonspecific pathophysiologic changes (e.g., fat infiltration, atrophy, edema, and fibrosis) respond to various muscle damages. MRI shows pathological changes of parenchymal alterations in muscle based on these major patterns of fat infiltration, atrophy, or edema.\cite{21} Our current results suggested that patients with late-onset MADD showed a rather homogenous pattern of muscle pathology on muscle MRI. Indeed, the majority of our patients presented a relatively homogenous involvement of posterior compartment of the lower limbs, mainly in posterior group and gluteus muscles [Figures 3, 4 and Supplement Table 1]. Using fat infiltration scoring, we found that the degree of fat infiltration in posterior group was significantly more severe than those in anterior and medial thigh muscle groups ($P < 0.001$). In addition, associated muscle atrophy was common. Similarly, muscular atrophy was more prominent in posterior group than other parts of thigh muscle groups. In addition to posterior group, fat infiltration and muscular atrophy were also identified in gluteus among most of the late-onset MADD patients.

On the contrary, few patients had the quadriceps femoris muscle involvement. Combing with the significant reduction of muscle strength in gluteus maximus, gluteus medius, and posterior group, it could be speculated that the degree of fat infiltration was consistent with the muscle strength. This pattern of muscle involvement may also provide indirect information about the disease process of late-onset MADD. We assume that the most frequently affected muscles, posterior group and gluteus, are affected earlier.

Table 2: Lower limbs muscle MRI changes of 28 late-onset MADD patients

| Lower limbs muscle MRI changes | Numbers of patients |
|-------------------------------|---------------------|
| Thigh                         |                     |
| Fat infiltration              |                     |
| Anterior thigh muscle group   | 9/28                |
| Medial thigh muscle group     | 21/28               |
| Posterior thigh muscle group  | 26/28               |
| Atrophy                       |                     |
| Anterior thigh muscle group   | 1/12                |
| Medial thigh muscle group     | 5/12                |
| Posterior thigh muscle group  | 12/12               |
| Edema                         | 0/28                |
| Gluteus muscles image available | 24/28              |
| Fat infiltration              | 15/24               |
| Atrophy                       | 15/24               |
| Edema                         | 0/24                |

Values are presented as n/N. MADD: Multiple acyl-coenzyme A dehydrogenation deficiency; MRI: Magnetic resonance imaging.

[Figure 4: T2-weighted (a, c, e, and g) and fat suppression images (b, d, f, and h) showed serious fat infiltrated regions (arrows) from a female with c.250G>A, c.770A>G compound heterozygous mutation on coronal scanning (a and b), anteroposterior axes of right thigh (c and d), horizontal scanning of pelvic (e and f) and thigh (g and h) level.]

[Figure 5: The mean of thigh muscle fat infiltration scores in three thigh muscle groups ($^*P < 0.01$, $^\dagger P < 0.001$).]
in the clinical course. In addition, muscle edema pattern, which is the most common characteristic performance of acute or recent muscle insult, was found in none of our patients. The MRI finding reflects a biologically chronic process in pathogenesis of this metabolic disorder and may be useful for differential diagnosis with other disease. The MRI features of thigh and gluteus muscles existed in patients with both homozygous mutations and compound heterozygous mutations.

The highly various clinical symptoms of patients with late-onset MADD easily lead to difficulty for diagnosis and confusion with other diseases, such as polymyositis, BMD, LGMD, and CMD. Even though genetic detection and muscle biopsy are necessary, they are invasive and unavailable in many hospitals. As a noninvasive and universal technique, muscle MRI can evaluate heterogeneous muscle involvement and has been utilized in many neuromuscular disorders for differential diagnosis. Although some neuromuscular disorders have similar MRI appearances, others have distinct patterns of signal intensity abnormality. The MRI characteristics of late-onset MADD summarized in our study provide valuable information for helping diagnosis. Clinical features of patients with polymyositis usually resemble that of late-onset MADD. However, patients with polymyositis present with widespread symmetrical muscle inflammation and prominent edema is the most prominent MRI finding, which is not found in late-onset MADD. In patients with DMD/BMD, progressive muscle hypertrophy and adductor magnus fat infiltration are the best characterized signs of muscle MRI, unlike the obvious involvement of posterior group and gluteus in late-onset MADD. The muscle MRI of LGMD patients varies from different subtypes with the heterologous gene mutations. A part of LGMD patients show that posterior compartment muscles in lower limbs affected while the fat infiltration is not as severe as that in late-onset MADD. The lower limbs muscle MRI of CMD shows diffuse fatty degeneration, especially in gluteus maximus muscle. In this regard, muscle MRI features, when correlated with clinical and laboratory findings, may facilitate a correct diagnosis to molecular screening of late-onset MADD.

In conclusion, late-onset MADD patients harboring ETFDH gene mutations presented an overall homogeneous pattern of muscle pathology on muscle MRI appearances, which are among the conditions associated with typical fat infiltration and atrophy. The majority of patients showed a consistent pattern on muscular imaging, with mild to severe involvement of the muscles of medial and posterior thigh compartment, as well as gluteus, and a sparing involvement of the anterior thigh compartment relatively. Our findings highlight diagnostic value of muscle MRI for late-onset MADD.

Acknowledgments
We sincerely thank the participants for their help and willingness to participate in this study and the anonymous reviewers that helped improve this manuscript.

Supplementary information is linked to the online version of the paper on the Chinese Medical Journal website.

Financial support and sponsorship
This work was supported by grants from the National Natural Science Foundation of China (No. 81271254 and U1505222), the National Key Clinical Specialty Discipline Construction Program, and Fujian Key Clinical Specialty Discipline Construction Program.

Conflicts of interest
There are no conflicts of interest.

References

1. Ohkuma A, Noguchi S, Sugie H, Malicdan MC, Fukuda T, Shimazu K, et al. Clinical and genetic analysis of lipid storage myopathies. Muscle Nerve 2009;39:333-42. doi: 10.1002/mus.21167.
2. Olsen RK, Andresen BS, Christensen E, Bross P, Skovby F, Gregersen N. Clear relationship between ETF/ETFDH genotype and phenotype in patients with multiple acyl-CoA dehydrogenation deficiency. Hum Mutat 2003;22:12-23. doi: 10.1002/humu.10226.
3. Watnough NJ, Freeman FE. The electron transfer flavoprotein: Ubiquinone oxidoreductases. Biochim Biophys Acta 2010;1797:1910-6. doi: 10.1016/j.bbabio.2010.10.007.
4. Xi J, Wen B, Lin J, Zhu W, Luo S, Zhao C, et al. Clinical features and ETFDH mutation spectrum in a cohort of 90 Chinese patients with late-onset multiple acyl-CoA dehydrogenase deficiency. J Inherit Metab Dis 2014;37:399-404. doi: 10.1007/s10545-013-9671-6.
5. Wang ZQ, Chen XJ, Murong SX, Wang N, Wu ZY. Molecular analysis of 51 unrelated pedigrees with late-onset multiple acyl-CoA dehydrogenation deficiency (MADD) in Southern China confirmed the most common ETFDH mutation and high carrier frequency of c.250G>A. J Mol Med (Berl) 2011;89:569-76. doi: 10.1007/s00109-011-0725-7.
6. Wen B, Dai T, Li W, Zhao Y, Liu S, Zhang C, et al. Riboflavin-responsive lipid-storage myopathy caused by ETFDH gene mutations. J Neurol Neurosurg Psychiatry 2010;81:231-6. doi: 10.1136/jnnp.2009.176404.
7. Henriques BJ, Rodrigues JV, Olsen RK, Bross P, Gomes CM. Role of flavinylation in a mild variant of multiple acyl-CoA dehydrogenation deficiency: A molecular rationale for the effects of riboflavin supplementation. J Biol Chem 2009;284:4222-9. doi: 10.1074/jbc.M805719200.
8. Mercuri E, Pichiecchio A, Counsell S, Allsop J, Cini C, Jungbluth H, et al. A short protocol for muscle MRI in children with muscular dystrophies. Eur J Paediatr Neurol 2002;6:305-7. doi: 10.1016/S1090379802906173.
9. Mercuri E, Messina S, Kinali M, Cini C, Longman C, Battini R, et al. Congenital form of spinal muscular atrophy predominantly affecting the lower limbs: A clinical and muscle MRI study. Neuromuscul Disord 2004;14:125-9. doi: 0096089663001986.
10. Sarkozy A, Deschauer M, Carlier RY, Schrank B, Seeger J, Walter MC, et al. Muscle MRI findings in limb girdle muscular dystrophy type 2L. Neuromuscul Disord 2012;22 Suppl 2:S122-9. doi: 10.1016/j.nmd.2012.05.012.
11. Wokke BH, van den Bergen JC, Versluis MJ, Niks EH, Mills J, Webb AG, et al. Quantitative MRI and strength measurements in the assessment of muscle quality in Duchenne muscular dystrophy. Neuromuscul Disord 2014;24:409-16. doi: 10.1016/j.nmd.2014.01.015.
12. Hafner P, Bonati U, Fischmann A, Schneider J, Frank S, Morris-Rosendahl DJ, et al. Skeletal muscle MRI of the lower limbs in congenital muscular dystrophy patients with novel POMT1 and POMT2 mutations. Neuromuscul Disord 2014;24:321-4. doi: 10.1016/j.nmd.2014.01.009.
13. Rosenbohm A, Süssmuth SD, Kassubek J, Müller HP, Pontes C, Abicht A, et al. Novel ETFDH mutation and imaging findings in an adult with glutaric aciduria type II. Muscle Nerve 2014;49:446-50. doi: 10.1002/mus.23979.
14. Liu XY, Wang ZQ, Wang DN, Lin MT, Wang N. A historical cohort study on the efficacy of glucocorticoids and riboflavin among patients with late-onset multiple acyl-CoA dehydrogenase deficiency. Chin Med J 2016;129:142-6. doi: 10.4103/0366-6999.173438.
15. Rider LG, Giannini EH, Harris-Love M, Joe G, Isenberg D, Pilkington C, et al. Defining clinical improvement in adult and juvenile myositis. J Rheumatol 2003;30:603-17. doi: 0315162X-30-603.
16. Ruperto N, Ravelli A, Murray KJ, Lovell DJ, Andersson-Gare B, Feldman BM, et al. Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. Rheumatology (Oxford) 2003;42:1452-9. doi: 10.1093/rheumatology/keg403.
17. Mercuri E, Lampe A, Allsop J, Knight R, Pane M, Kinali M, et al. Muscle MRI in Ullrich congenital muscular dystrophy and Bethlem myopathy. Neuromuscul Disord 2005;15:303-10. doi: S0960-8966(05)00024-6.
18. Mercuri E, Pichiocchio A, Allsop J, Messina S, Pane M, Muntoni F. Muscle MRI in inherited neuromuscular disorders: Past, present, and future. J Magn Reson Imaging 2007;25:433-40. doi: 10.1002/jmri.20804.
19. Kim HK, Laor T, Horn PS, Racadio JM, Wong B, Dardzinski BJ. T2 mapping in Duchenne muscular dystrophy: Distribution of disease activity and correlation with clinical assessments. Radiology 2010;255:899-908. doi: 10.1148/radiol.10091547.
20. Cox FM, Reijnierse M, van Rijswijk CS, Wintzen AR, Verschuuren JJ, Badrising UA. Magnetic resonance imaging of skeletal muscles in sporadic inclusion body myositis. Rheumatology (Oxford) 2011;50:1153-61. doi: 10.1093/rheumatology/ker001.
21. Mumtaz HA, Gupta V, Singh P, Marwaha RK, Khandelwal N. MR imaging findings of glutaric aciduria type II. Singapore Med J 2010;51:e69-71.
22. Kana V, Kellenberger CJ, Rushing EJ, Klein A. Muscle magnetic resonance imaging of the lower limbs: Valuable diagnostic tool in the investigation of childhood neuromuscular disorders. Neuropediatrics 2014;45:278-88. doi: 10.1055/s-0034-1381954.
23. Yao L, Yip AL, Shrader JA, Deseghini S, Volochayev R, Jansen AV, et al. Magnetic resonance measurement of muscle T2, fat-corrected T2 and fat fraction in the assessment of idiopathic inflammatory myopathies. Rheumatology (Oxford) 2016;55:441-9. doi: 10.1093/rheumatology/kev344.
24. Hicks D, Sarkozy A, Muelas N, Koehler K, Huebner A, Hudson G, et al. A founder mutation in anoctamin 5 is a major cause of limb-girdle muscular dystrophy. Brain 2011;134(Pt 1):171-82. doi: 10.1093/brain/awq294.
### Supplement Table 1: Thigh muscle fat infiltration scores of 28 late-onset MADD patients

| Number | Number | Anterior thigh muscle group | Medial thigh muscle group | Posterior thigh muscle group | Total |
|--------|--------|-----------------------------|--------------------------|-------------------------------|-------|
|        |        | Sartorius | Rectus femoris | Vastus lateralis | Vastus intermedius | Vastus medialis | Gracilis | Adductor longus | Adductor brevis | Adductor magnus | Biceps femoris | Semitendinosus | Semimembranosus |
| 1      | 0      | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 3 | 3 | 0 | 10 |
| 2      | 2      | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 3 | 3 | 0 | 10 |
| 3      | 0      | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 0 | 10 |
| 4      | 0      | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 0 | 10 |
| 5      | 0      | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 2 | 1 | 0 | 2 |
| 6      | 1      | 0 | 1 | 0 | 0 | 0 | 2 | 1 | 0 | 2 | 2 | 2 | 2 | 13 |
| 7      | 1      | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 3 | 2 | 3 | 2 | 15 |
| 8      | 0      | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 4 |
| 9      | 0      | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 1 | 5 |
| 10     | 0      | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 2 |
| 11     | 0      | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 12     | 0      | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 13     | 0      | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 14     | 1      | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 2 | 1 | 8 |
| 15     | 0      | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 2 | 1 | 1 | 1 | 5 |
| 16     | 0      | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 2 | 0 | 5 |
| 17     | 0      | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 18     | 1      | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 2 | 2 | 1 | 8 |
| 19     | 1      | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 2 | 3 | 3 | 3 | 16 |
| 20     | 0      | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 1 | 7 |
| 21     | 0      | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 2 | 1 | 2 | 0 | 8 |
| 22     | 2      | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 1 | 0 | 3 |
| 23     | 0      | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 2 |
| 24     | 1      | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 2 | 2 | 2 | 1 | 10 |
| 25     | 0      | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 2 | 2 | 3 | 1 | 9 |
| 26     | 0      | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 2 | 1 | 6 |
| 27     | 0      | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 5 |
| 28     | 0      | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 1 | 6 |

MADD: Multiple acyl-coenzyme A dehydrogenation deficiency.